The grant of $600,000 is expected to support the research to characterize the role of the phosphoinositide 3-kinase (PI3K) in preclinical models of skin autoimmune inflammation.
Dynavax vice president and chief scientific officer Robert Coffman said this new grant supports preclinical studies focused on this key component of the TLR signaling pathway as a target for the treatment of inflammatory skin disorders.
"This work could well be complementary to our GSK development partnership focused on TLR inhibitors," Coffman said.